4.8 Article

Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 75, Issue 3, Pages 365-379

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/S0168-3659(01)00405-9

Keywords

N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer; anticancer drug; camptothecin; colon-specific drug delivery; drug release

Funding

  1. FIC NIH HHS [TW00991] Funding Source: Medline
  2. NIDDK NIH HHS [DK39544] Funding Source: Medline

Ask authors/readers for more resources

N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates for colon-specific delivery of 9-aminocamptothecin (9-AC) were designed. They hold 9-AC bound via spacers containing amino acid residues and aromatic azo bonds. In vitro release profiles of 9-AC from HPMA copolymer conjugates were evaluated under artificial conditions that simulated large intestinal azoreductase and peptidase activities. The studies indicated that the azo bond was reduced first, followed by the release of unmodified 9-AC from the 9-AC containing fragment by peptidases. Release profiles depended on the chemical structure of the peptide part of the spacer. Conjugates containing leucylalanine showed high colon-specific release of 9-AC when compared to alanine containing conjugates. It appears that the studied conjugates are suitable as colon-specific drug delivery systems. (C) 2001 Elsevier Science BY All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available